The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma?
- PMID: 21082214
- PMCID: PMC3361714
- DOI: 10.1007/s11060-010-0449-5
The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma?
Abstract
It seems quite clear that microRNAs play important roles in neuro-oncology, as they do across perhaps all areas in biology. With recent advances in detecting and quantifying microRNAs in tissue and serum, it appears increasingly likely that microRNAs will be clinically useful as biomarkers for brain tumors and other cancers. Applying microRNAs for treatment of brain tumors poses greater hurdles by far, however, and despite promising in vitro results this may never become a reality. This review fits recent advances into a framework for considering the potential of microRNAs for brain tumor therapy, considering the power of individual microRNAs, delivery issues, and indirect microRNA-based therapies.
Figures
References
-
- Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811. - PubMed
-
- Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001;106:23–34. - PubMed
-
- Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science. 1999;286:950–952. - PubMed
-
- Hammond SM, Bernstein E, Beach D, et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000;404:293–296. - PubMed
-
- Ambros V. A hierarchy of regulatory genes controls a larva-to-adult developmental switch in C. elegans. Cell. 1989;57:49–57. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources